Making Genomics Data
Actionable
● Clinical-Grade Genetic Predispositions for 236 Health
Conditions
● Genetics Specific Intervention Recommendations
● Genetics Combined With Conventional BioMarkers &
Lifestyle assessments
www.selfdecode.com
Ralph Kenney - COO
ralph@selfdecode.com
+382 69 828 382
Snapshot
Problem
1 out 5 Americans already have their DNA. But
the data is largely useless because genomics
data is not actionable for most common
health conditions. This costs billions of dollars
annually, reduces Quality of Life and results in
millions of premature deaths.
Solution
A genomics platform providing
clinical-grade genetics interpretation and
genetics-specific care recommendations
as a service, enabling health tech
businesses and health providers to easily
build precision health solutions.
Market Size
Total addressable Market in North America only
-$21.8B per year.
Traction
$2.7 m in annual revenue
Genomics database of over 800,000 genomes
17,000 highly engaged subscribers
Over 500 healthcare practitioners using the platform
20 B2B contracts signed, valued at $38 M over the next 5 years
Industry leading PRS, Genetic Imputation, Data Compression and
Ancestry determination (based on competitive benchmarking)
● 3 patents to be filed Q4/22
●
●
●
●
●
●
Raising $8M
The Problem In Short…
We’ve made tremendous strides in understanding and interpreting the
human genome and the cost of genetic testing is now affordable to
almost everyone. 1 out 5 Americans already have their DNA.
However, genomics remains on the fringe of health because
interpreting and recommending actions based on genomics requires
specialized knowledge and technology costing millions of dollars.
Health care providers and consumers are left struggling to
understand and act on genetic data.
This results in preventable illness, delays in treatment and lives lost.
You don’t have to take our word for it.
By combining hundreds to thousands of common genetic variants, each explaining a (usually small) proportion of
the disease, PRS can now explain up to 20–50% of the occurrence of common diseases. … But DNA analysis is so
far only used in specialized settings and for a limited number of health problems and, thus, is still not
capitalizing on its full potential. (European Journal of Human Genetics- Feb. 2022)
because…
As genomic data become more widely available, health care providers struggle to interpret
genomic results (J. of Molecular Diagnostics - Jan. 2022)
This costs thousands of lives annually. As just one example…
Individuals classified in the highest risk group by GPS-CAD (Polygenic Risk) appeared to have roughly
77 percent greater risk of Sudden Arryhthmic Death compared with those classified into other risk
tiers. (J. of the American College of Cardiology - May 2022)
Targeted assessment only among people at intermediate (i.e., 5% to 10%) 10-year CVD risk could help
prevent 1 additional CVD event for approximately every 340 individuals screened and prevent 7% of
acute CVD events.
Solution:
A genomics platform
providing clinical-grade
genetics interpretation and
genetics-specific
recommendations as a
service, enabling health
tech businesses and health
providers to easily build
precision health solutions.
Industry Leading Genetics Science
● Based on inexpensive genotyping technology,
● Proprietary (patentable) ancestry determination to the sub-population level,
● Proprietary (patentable) imputation of approximately 83 million genetic
variants,
● Clinical-grade, ancestry-portable polygenic risk scoring for over 236
common health conditions,
● Collection of and tracking of longitudinal conventional biomarkers,
● Collection of self-assessment data,
● GWAS-based non-medical risk mitigation recommendations.
All this science….
Presented in way anyone
can understand
SelfDecode DTC
Total Addressable
Market (USA Only)
$21.6 B
/ Year
The North American DTC Genetic Testing Market was $1.4 B in 2021 with a
CAGR 15.3%. Projected value by 2028 is $4.2 B.
Focusing narrowly on functional medicine practitioners, with an estimated
average annual platform spend of $22,320. We project a North American
practitioner TAM of $7.8 B annually.
Excluding oncology and therapeutics, the precision medicine market is projected at
$40.3B by 2028. We focused on just the genetic testing segment for a B2B TAM of
$9.6B.
Our GTM Strategy
● SelfDecode becomes the “AWS” of
Genomics. Genomics- As-A-Service
Revenue, Brand Recognition,
Market Validation, Feature
Testing
Proof of Concept, Core
Capabilities
(GAAS)
● Leverage SelfDecode DTC for Proof of
Concept, Data Collections and Brand
Building
DTC
(SelfDecode)
SelfDecode
Genomics
Platform
● Grow Core Capabilities Based on
Successful B2B Partnerships
New Features, Market Data
B2B
(SD-Pro /
Omics Edge)
Sales Strategy
Targeting: DTC Genetics, Practitioner Networks & Hospital Systems, Health Tech, Employee Benefits and
Insurance
Business Development:
●
In-House Business Development in High-Value Markets,
●
Distributors in Emerging Markets
●
Health Tech, BioTech and Precision Medicine Conferences,
Marketing: Publishing Peer-Reviewed Research, Leadership pieces in relevant media, Co-Branding
Pricing: One time API-fee, Recurring Revenue through pay-as-you-go services, customized development
creates stickiness.
What makes SelfDecode different?
Technology
Benefit
Clinical-Grade Polygenic Risk Scores
Partners, physicians and consumers receive genetic predisposition scores with clinical utility and
accuracy
PRS Models for Over 200 Common
Health Conditions
Genomics data on the common conditions affecting millions of people, not “rare” diseases affecting a
few thousands
Portable Across Ancestry
Actionable genomics for everybody not just one ethnicity
Imputation of 83 Million SNPs
Genomics insights affordable to all
100:1 Genetic Data Compression
Enables storage and transmission of genetics data at scale
Genetic Specific Recommendations
Provides partners, physician and consumers with genetics-specific actionable steps
Combines Genetics With
Conventional Labs and
Self-Assessments
Enables users to apply genetics data to more familiar bioinformatics data points. Additive data
instead of alternate data
RESTFUL API
Genomics insights and recommendations as a service makes building health applications that use
genomics affordable and possible for ANY health tech business
SelfDecode’s
DTC Experience
Validates The
Utility of PRS for
Consumer Health
● Engagement: ⅔ of our subscribers
have logged in in the last 90 days, ½ of
those, logged in 4 or more times.
● Satisfaction: Trustpilot score of 4.9 out
of 5.
● Effectiveness: Analysis of customer
uploaded lab data show significant
improvements for those customers in
the highest risk. (see appendix)
● AND…
Our subscribers say SelfDecode works!
SelfDecode
23andMe
Prenetics
(CircleDNA,
DNAFit)
Color
Genomic plc
1314
150+
500+
3
Not Reported
#SNPs / report
Up to 1.2M
< 1000
< 100
< 74
Not Reported
Polygenic Risk
Scoring
✔
No
No
No
Limited, Not At
Scale
Ancestry-Informed
PRS
✔
No
No
No
Not Stated
Genetic Specific
Recommendations
✔
No
No
No
Drugs-Only
Incorporates Labs
✔
No
No
Some
No
Includes Lifestyle
Assessments
✔
No
No
No
Limited
Benefits
# of reports
Our Leadership Team
The leadership team is led by Joe Cohen, who won the
genetic lottery of bad genes and decided to embark on a
journey of self-experimentation and self-learning to
improve his health- something that has since become
known as “biohacking”. With thousands of experiments and
pubmed articles under his belt, Joe founded SelfHacked,
the resource that was missing when he needed it.
SelfHacked now gets millions of monthly readers. Joe is a
thriving entrepreneur, author and speaker. He is the CEO of
SelfHacked, SelfDecode and LabTestAnalyzer. His mission
is to help people gain access to the most up-to-date,
unbiased, and science-based ways to optimize their health.
Supporting him are industry veterans Dr. Puya Yazdi (CSO);
Ralph Kenney (COO)
Our Science Team
Manfred
Grabherr, PhD
Charles
Manson, PhD
Biljana
Novkovic,
PhD
Joe Lerga
Jaso, PhD
Lewis
Cuthbertson,
PhD
Deepu
Unnikrishnan,
MSc
Abdallah
Mahmoud,
BSc
VP of
Bioinformatics
and AI
AI Research
Scientist
Senior Precision
Medicine Scientist
and Director of
Research &
Development
Bioinformatics
Scientist
Science Writer
Data Scientist
Bioinformatics
Engineer
Laurent
Dufloux, PhD
Carlos Tello
Lascal, PhD
Alex Osama,
BSc
Sandra Bohn,
MSc
Varuna
Andrew
Terpolovsky,
MSc
Adriano De
Marino, PhD
Senior
Bioinformatics
Engineer
Bioinformatics
Scientist and
Team Lead
Dr. Puya Yazdi, MD
CHIEF SCIENTIFIC OFFICER
MD from USC, Stanford
Residency. 15+ years of success
in R&D, IP acquisition & science
publications in genomics,
bioinformatics, biotech &
precision medicine. 10+
precision medicine products.
7+ years of executive
experience.
Bambunusinghe,
BSc
Big Data Engineer
Research &
Development
Scientist
Data Scientist
Big Data Engineer
Senior AI Engineer
and Team Lead
Traction
● Revenue of $2.7 M (trailing 12 month)
● 17,000 DTC Subscribers, ALTV $400, 98% Retention, TrustPilot score 4.9/5
● Over 500 Health Practitioners using SelfDecode-Pro
● 18 signed B2B contracts totaling customer-estimated revenue of over $32.8 M over the next 5 years
● Ancestry Model Benchmarks 20% Better Than Known Models
● Imputation Outperformed All Other Academic and Commercial Models in Benchmarking by 22%
● PRS Model Before Integration of Ancestry and Imputation Already Performs 5% Better
● Industry-Leading Genetics Data Compression at 100:1 without loss
● 3 Patents to be filed in Q4/2022
Partial List of B2B Customers
Fundable Milestones
International Patents for Data Compression, Ancestry and Imputation - $500K
Expanded marketing - $1M
Development & Validation of Absolute Risk Score Models - $2M
Pharmacogenomics - $500K
Acquire additional validation data - $500K
Disease Reports - $450K
Apply for LDT Approvals - $700K
Improved OCR - $100K
Functionality Expansion SelfDecode Pro - $750K
Internationalization - $500K
Expand and Train Bus-Dev Team - $750K
Sec./GDPR/HIPAA certifications - $250K
Total Funding Requirement - $8M
That’s just the beginning…
Our Moonshots
● Enabling Genomics-Based CDS in the EHR
● Laboratory Developed Test Pipeline Based on Combining Genomics and
Conventional Biomarkers
● Reversal of the PRS models for Drug Discovery
We Make
Precision Health
Possible
Ralph Kenney - COO | ralph@selfdecode.com | +382 69 828 382
Omics Edge
PRS Advantage
PRS
Benchmarking
Omics Edge
PRS Advantage
Ancestry
Benchmarking